John Glaser and How AI is Affecting Electronic Medical Records Systems

10/26/18 • 34 min

Harry's guest John Glaser, senior vice president of Population Health at Cerner, speculates on how business models in healthcare are changing and how artificial intelligence and EMR systems will work together in the future.

Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:

1. Open the Podcasts app on your iPhone, iPad, or Mac.

2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.

3. Scroll down to find the subhead titled "Ratings & Reviews."

4. Under one of the highlighted reviews, select "Write a Review."

5. Next, select a star rating at the top — you have the option of choosing between one and five stars.

6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.

7. Once you've finished, select "Send" or "Save" in the top-right corner.

8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.

9. After selecting a nickname, tap OK. Your review may not be immediately visible.

That's it! Thanks so much.

Transcript

Harry Glorikian: Welcome to the Money ball medicine podcast. I'm your host Harry Glorikian, this series is all about the data-driven transformation of the healthcare and life sciences landscape. Each episode we dive deep through one-on-one interviews with leaders in the new cost-conscious, value-based healthcare economy. We look at the challenges and opportunities they're facing and their predictions for the years to come.

My guest today is John Glaser, who is the senior vice president of Population Health at Cerner. Cerner is a health IT company that is one of the largest suppliers of electronic health record systems in the United States. John joined Cerner in 2015 as part of the Siemens health services acquisition, where he was the chief executive officer. Prior to Siemens, John was vice president and chief information officer at Partners HealthCare. He also previously served as vice president of information systems at Brigham and Women's Hospital.

John received his PhD from the University of Minnesota, he has written over 200 articles and three books on the strategic application of IT and health care. Including the most widely used textbook on the topic, “Healthcare information systems a practical approach for health care”. John is on the faculty of the Wharton School at the University of Pennsylvania, the medical university of Southern Carolina, the School of biomedical informatics at the Texas Health Science Center and the Harvard School of Public Health.

John focuses on strategic relationships with Cerner clients and advancing Cerner's population health solutions and services. John, welcome to Moneyball medicine, it's great to have you here.

John Glaser: Harry, it's a pleasure.

Harry Glorikian: John, tell me what does it mean to be vice president of Population Health. What is Population Health?

John Glaser: Well, it's a fuzzy term in some ways but basically the idea is that there are organizations. They'd say I'm accountable for the health care and the health of a group of people, it might be an employer who says I'm responsible for my employees or the state Department or a health care provider, who has a series of lives attributed to the - health plan, but the point is they're accountable. And so they need a series of tools and technologies that help them manage health and manage health care this is analytics to see you know who's receiving what care, how costly is it.

This is a series of care management to the degree they need someone to help them navigate the care process or social determinants. So anyway, at the end of the day accountable organizations need technology to help them fulfill their obligations to those who they are to serve, and that's what population health IT staff intends to do.

Harry Glorikian: You know medicine has been historically based on a fee-for-service model, where you're paid on what you do. And now that we've seen sort of a shift not as much as I'd like to see, but a shift towards value-based medicine, in other word...

Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:

1. Open the Podcasts app on your iPhone, iPad, or Mac.

3. Scroll down to find the subhead titled "Ratings & Reviews."

4. Under one of the highlighted reviews, select "Write a Review."

5. Next, select a star rating at the top — you have the option of choosing between one and five stars.

6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.

7. Once you've finished, select "Send" or "Save" in the top-right corner.

8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.

9. After selecting a nickname, tap OK. Your review may not be immediately visible.

That's it! Thanks so much.

Transcript

John focuses on strategic relationships with Cerner clients and advancing Cerner's population health solutions and services. John, welcome to Moneyball medicine, it's great to have you here.

John Glaser: Harry, it's a pleasure.

Harry Glorikian: John, tell me what does it mean to be vice president of Population Health. What is Population Health?

Previous Episode

Dekel Gelbman and How Machine Learning Is Changing Rare Disease Diagnosis

Harry's guest is Dekel Gelbman, founding CEO of FDNA. The company uses a combination of computer vision, deep learning, and other artificial intelligence techniques to improve and accelerate diagnostics and therapeutics for children with rare diseases.

Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:

1. Open the Podcasts app on your iPhone, iPad, or Mac.

3. Scroll down to find the subhead titled "Ratings & Reviews."

4. Under one of the highlighted reviews, select "Write a Review."

5. Next, select a star rating at the top — you have the option of choosing between one and five stars.

6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.

7. Once you've finished, select "Send" or "Save" in the top-right corner.

8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.

9. After selecting a nickname, tap OK. Your review may not be immediately visible.

That's it! Thanks so much.!

Note: MoneyBall Medicine is produced for the ear and designed to be heard. If you are able, we strongly encourage you to listen to the audio, which includes emotion and emphasis that's not on the page. Transcripts are generated using a combination of speech recognition software and human transcribers and may contain errors. Please check the corresponding audio before quoting in print.

Transcript

Harry Glorikian: Welcome to the Moneyball medicine podcast...

I'm your host Harry Glorikian. This series is all about the data-driven transformation of the healthcare and life sciences landscape. Each episode we dive deep through one-on-one interviews with leaders in the new cost-conscious value-based healthcare economy. We look at the challenges and opportunities they're facing and their predictions for the years to come.

My guest for today is Dekel Gelbman, who is the founding CEO of FDNA. He leads the corporate and business strategy of an innovative digital health company that develops technologies and SAS platforms used by thousands of clinician’s researchers and lab sites locally in the clinical genomic space. The main mission of the company is to give hope to children with rare diseases and their families.

FDNA which was founded in 2011, uses a combination of computer vision, deep learning, and artificial intelligence to analyze patient symptoms, physical features and genomic data in combination with a network of thousands of genetics professionals worldwide. Then they drive scientific insights to improve and accelerate diagnostics and therapeutics impacting the lives of children with rare diseases.

Harry Glorikian: Dekel, welcome to the show, good to have you.

Dekel Gelbman: Thank you very much, it's a pleasure being here.

Harry Glorikian: Dekel, we've known each other almost since the day you showed up here in Boston deciding whether you would place yourselves here as a company. Tell me how this whole thing got started, because it's not exactly what you would consider a normal route into the world of diagnostics or using AI and machine learning, and it was quite a while back. I mean it will you were guys were at the forefront of this before I think a lot of other people got involved.

Dekel Gelbman: Absolutely you know, when we started we knew almost nothing about healthcare. We were techies, the background of this company was actually two founders that were very successful in developing facial recognition software that was sold to Facebook in early 2010s. And the drive, I think for this company was how do we make an impact, real social impact with this technology or with our know-how around facial recognition. And so by exploring a lot of fields, Healthcare was really very compelling because of the impact that you can, you can make and we started to meet with various specialists and different practices in health care. And then almost by accident, we stumbled across genetics and we were amazed to learn that back then and for decades’ geneticists would look at faces of patients and make a lot of the diagnostic ...

Next Episode

Leah Binder on How Price and Quality Transparency Helps Patients and Employers

Leapfrog Group president and CEO Leah Binder talks with Harry about data transparency and how it helps inform healthcare decisions by putting the right information in the hands of patients and employers.

Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:

1. Open the Podcasts app on your iPhone, iPad, or Mac.

3. Scroll down to find the subhead titled "Ratings & Reviews."

4. Under one of the highlighted reviews, select "Write a Review."

5. Next, select a star rating at the top — you have the option of choosing between one and five stars.

6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.

7. Once you've finished, select "Send" or "Save" in the top-right corner.

8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out.

9. After selecting a nickname, tap OK. Your review may not be immediately visible.

That's it! Thanks so much.

Transcript

Harry Glorikian: Welcome to the Money ball medicine podcast, I'm your host Harry glory camp. This series is all about the data-driven transformation of the healthcare and life sciences landscape. Each episode we dive deep through one-on-one interviews with leaders in the new cost-conscious, value-based healthcare economy. We look at the challenges and opportunities they're facing and their predictions for the years to come.

So, my guest today is Leah Binder, Leah is the president and CEO of the Leapfrog Group. The Leapfrog Group represents employers and other purchasers of health care who call for improved safety and quality and hospitals. She is a regular contributor to forbes.com, The Huffington Post and The Wall Street Journal expert forum. She was named on Becker's list of the 50 most powerful people in healthcare in 2014, and consistently cited by modern health care among the 100 most influential people and top 25 women in healthcare.

She has served on numerous national boards and councils including the Institute of Medicine collaboration on patient engagement, the Health Care Financial Management Association Leadership Advisory Committee, but Corey healthcare systems advisory panel, AARP champions for Nursing strategic advisory council and the national priorities partnership board. Prior to her current position, she spent eight years as vice president at Franklin Community Health Network an award-winning rural hospital network in Farmington Maine.

he previously worked as a senior policy adviser for the office of mayor Rudolph Giuliani in New York City and started her career at the National League for nursing, where she handled policy and communications for more than six years. Thank you very much for joining me today, good to have you here.

Leah Binder: Well, thank you for having me, it's a privilege.

Harry Glorikian: So, we had spoken quite a bit back when I was putting together the book Money ball medicine but for those people who are not familiar with the Leapfrog Group, can you tell us a little bit about the group its mission and what you feel the biggest impacts are it's made to date?

Leah Binder: Sure and I want to congratulate you by the way on your book, I really thought it was fantastic. I've been giving it out to a lot of my colleagues I strongly recommend it. So, congratulations on an excellent book, I think it really captured some very important issues about where we are in healthcare right now. So, it's a great contribution.

Harry Glorikian: Thank you so much.

Leah Binder: The Leapfrog Group is a non-profit, we were national. We were founded in the year 2000 by a group of senior executives in large companies, who were concerned about healthcare quality and costs. They were particularly concerned about a report that came out from the Institute of Medicine, right around that time that was called to air is human. Which said that, upwards of a hundred thousand people were dying of preventable medical errors in hospitals every year.

And they were astounded by that number not...